Related Experiment Video
Updated: Jul 26, 2025

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Towards an Open-Source Platform to Harmonize and Share Research Results from COVID-19 Interventional and
Irena Parvanova1, Kirill Borziak1, Joseph Finkelstein1
1Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Abstract:
As the SARS-CoV-2 virus continues to remain a universal threat on a global scale, a large number of COVID-19 clinical trials and observational studies are being conducted and published. Currently, 9,202 COVID-19 clinical trials have been registered on ClinicalTrials.gov and 293,187 COVID-19 articles were indexed in PubMed. To fully capitalize on the voluminous number of publications reporting COVID-19 interventional and observational studies, their results should be freely accessible via an open-source harmonized shared resource. We introduced ReMeDy (https://remedy.mssm.edu/), an intelligent integrative informatics platform aimed to harmonize and cross-link diverse COVID-19 trial outcomes and observational data. We tested the potential of the platform by uploading 52 COVID-19 clinical trials and 48 COVID-19 observational retrospective studies. ReMeDy was validated based on its capability to store and organize diverse data. The next steps include developing a crowdsourcing functionality coupled with automated outcome extraction using natural language processing.
Related Concept Videos
Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
Statistical Software for Data Analysis and Clinical Trials
Clinical Trials
There are four phases in a clinical trial. A phase one...
Statistical Methods for Analyzing Epidemiological Data
Clinical Trials: Overview
Principles of Disease Surveillance

